First Wave Biopharma Stock Net Asset
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
First Wave BioPharma fundamentals help investors to digest information that contributes to First Wave's financial success or failures. It also enables traders to predict the movement of First Stock. The fundamental analysis module provides a way to measure First Wave's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to First Wave stock.
First |
First Wave BioPharma Company Net Asset Analysis
First Wave's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current First Wave Net Asset | 6.88 M |
Most of First Wave's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, First Wave BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, First Wave BioPharma has a Net Asset of 6.88 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
First Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses First Wave's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of First Wave could also be used in its relative valuation, which is a method of valuing First Wave by comparing valuation metrics of similar companies.First Wave is currently under evaluation in net asset category among its peers.
First Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 72.56 M | |||
| Shares Outstanding | 2.03 M | |||
| Shares Owned By Insiders | 5.66 % | |||
| Shares Owned By Institutions | 1.46 % | |||
| Number Of Shares Shorted | 46.6 K | |||
| Price To Book | 1.87 X | |||
| EBITDA | (15.74 M) | |||
| Net Income | (15.79 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.83 X | |||
| Total Debt | 826.84 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | 7.99 X | |||
| Cash Flow From Operations | (12.38 M) | |||
| Short Ratio | 1.02 X | |||
| Earnings Per Share | (47.88) X | |||
| Target Price | 36.0 | |||
| Beta | 1.28 | |||
| Market Capitalization | 5.99 M | |||
| Total Asset | 6.88 M | |||
| Retained Earnings | (184.33 M) | |||
| Working Capital | 1.82 M | |||
| Net Asset | 6.88 M |
About First Wave Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze First Wave BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of First Wave using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of First Wave BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |